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Abstract  
Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a 
relatively unknown disease to the most common cause of CLD in the world. In fact, 25% of 
the world’s population is currently thought to have NAFLD. Non-alcoholic steatohepatitis  
(NASH) is the subtype of NAFLD that can progress to cirrhosis, hepatocellular carcinoma,  
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and death. NAFLD and NASH are found in not only adults—there is a high prevalence in 
children and adolescents. Due to NAFLD’s close association with type 2 diabetes (T2DM) 
 and obesity, the latest models predict the prevalence of NAFLD and NASH will increase, 
causing a tremendous clinical and economic burden and poor patient-reported outcomes. 
Nonetheless, there is no accurate non-invasive method to detect NASH and treatment is 
limited to life style modifications. To examine the state of NAFLD among different regions 
and understand the global trajectory of this disease, an international group of experts came 
together during 2017 AASLD Global NAFLD Forum. We provide a summary of this forum 
and an assessment of the current state of NAFLD and NASH worldwide.   
Introduction  
Over the past three decades, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic 
steatohepatitis (NASH) have gone from obscure liver diseases with histologic features similar 
to alcoholic liver disease to the most prominent cause of CLD worldwide (1,2). In fact, after 
its first description, there was initial skepticism that NASH was a real liver disease (3). In the 
1990s, it became evident that NASH was part of the NAFLD spectrum, but with specific 
histopathology and potential for progression (4).   
Over the next decade, it became increasingly clear that NASH is the hepatic manifestation of 
metabolic syndrome and is highly prevalent in obese and diabetic subjects (5). Additionally, 
the increasing number of components of metabolic syndrome appear to increase the risk of 
progression to NASH (6,7). In contrast to NAFLD from Western countries, data from Asia 
indicate that a proportion of patients with NASH, especially from the rural regions, do not 
meet the criteria for obesity and have “lean NAFLD” (8).   
In 2018, it is estimated that about 25% of the world population has NAFLD (9) (Figure 1). 
Several studies investigated progression of NAFLD and its subtypes (4, 10-19). Although 
most studies have concluded that NASH is the progressive form, recent data indicate that a 
small subset of NAFLD without histologic features of NASH can develop progressive liver 
 disease (11). NASH is already considered among the top etiologies for hepatocellular 
carcinoma (HCC) and indications for liver transplantation (LT) in the United States (U.S.) 
(1,20-21).  
 Progression of NASH does not seem to be linear or simple—patients seem to have 
spontaneous progression and regression of liver disease over a long period of time (11). 
Although factors related to metabolic syndrome, especially presence of T2DM, seem to 
promote progression (3, 6), factors independently associated with spontaneous regression of 
NASH and NASH-related fibrosis are not fully described. However, the most current data 
indicate a tight association between increasing prevalence of T2DM and progressive NASH. 
In fact, given the increasing global epidemic of obesity and T2DM, a recent model has 
estimated a 178% increase in liver deaths related to NASH by 2030 (13).   
In addition to liver-related mortality and morbidity, NAFLD and NASH are associated with 
several extrahepatic manifestations, adding to the burden of disease (Figure 2) (16). As our 
clinical and epidemiologic understanding increases, clinical burden of NAFLD and NASH 
related to its prevalence, incidence, and progressiveness must be coupled with its tremendous 
economic burden, and its negative effects on patient-reported outcomes (PROs) (14).   
Currently, there is no approved drug regimen to treat NASH (17). As a consequence of the 
lack of treatment and the growing global epidemic of obesity, the prevalence of NAFLD is 
likely to increase, creating a serious health crisis in the next few decades. Given this global 
burden, we summarize the data on NAFLD and NASH from different global regions.  
Prevalence in the Americas   
The prevalence of NAFLD in the general population of North America has been estimated to 
be approximately 24% (9, 18). In contrast, the prevalence of NAFLD in South America is 
 32% (9). The prevalence of NAFLD varies among countries in Central and South America, 
depending on the prevalence of obesity. The lowest prevalence of NAFLD in this region has 
been reported from Peru (12.5%) with only 15% of the population being obese, while the 
highest prevalence is reported from Belize at 29% with 35% being obese (9).  
In addition to obesity, other factors may contribute to the prevalence and outcomes of  
NAFLD such as genetic factors, including those associated with Native American and 
Hispanic heritage. (1-8) A study that compared NAFLD in Hispanics of Mexican origin vs 
those of Caribbean origin (Dominican Republic and Puerto Rican) reported that Hispanics of 
Mexican origin had a higher prevalence of NAFLD (33%) than Hispanics of Dominican 
origin (16%) or Puerto Rican origin (18%), (P<.01). After controlling for age, sex, body mass 
index (BMI), waist circumference, hypertension, serum level of high-density lipoprotein, 
levels of triglyceride and C-reactive protein, and insulin resistance, Hispanics of Mexicans 
remained more likely to have NAFLD than those of Dominican or Puerto Rican origin (23). 
A high prevalence of a polymorphism in the gene encoding patatin-like phospholipase 
domain-containing 3 (PNPLA3; rs738409 C/G, M148I) in Hispanics has been proposed to 
contribute to the high prevalence of NAFLD (1). Nonetheless, given the increasing trends of 
obesity, T2DM, and the pediatric NAFLD in the Latin America, it is expected that the 
NAFLD-associated liver disease burden will increase significantly.  
Because of histologic requirements, we do not have accurate data on the prevalence of  
NASH. In the general US population, the prevalence of NASH is estimated between 1.5% to 
6.45% (9). Although there are substantial efforts in the U.S. to understand NASH, its 
biomarkers and drug treatment, a great number of challenges remains. Some of the efforts are 
undertaken by AASLD, FDA, NIH, Liver Forum and chronic liver disease foundations to 
address end points and biomarkers in NASH. Nevertheless, the most important challenge in 
 the U.S. is developing a national policy to address the epidemic of obesity, the main culprit 
that fuels the growing burden of NAFLD.  
Prevalence in Europe  
The prevalence of NAFLD has been estimated at 20%–30% in the European Union, with 
approximately 3% having NASH. (9) NAFLD prevalence rates varies from different 
European countries.  A population-based study from the North-Eastern rural part of Germany 
determined the prevalence of fatty liver by ultrasound to be 29.9%. Only15.9% of these 
patients had increased levels of serum alanine aminotransferase, supporting the concept that 
prevalence of NAFLD can vary with diagnostic methods (22).  Similar rates have been 
described in the general population of Northern Italy with 25% having NAFLD by ultrasound 
(23). Again, 5.9% to 54% of NAFLD had increased alanine aminotransferase (24). In 
addition, similar rates have been reported from Spain (25.8%) (25) and UK (26.4%) (26).   
In Eastern Europe, the prevalence of NAFLD by ultrasound was 22.6% in Hungary (27) and  
20% in Romania (28). Similar to other regions, prevalence of NAFLD in Europe increases 
with BMI, 25% (BMI<25kg/m2), 67% (BMI 25–30 kg/m2) and 91% (BMI ≥30 kg/m2). (29)  
Similarly, risk factors for NAFLD (obesity or T2DM) are increasing in Europe, fueling its 
complications of cirrhosis and HCC (30-36).  
In Europe, the most urgent challenge is to establish a set of biomarkers that, singly or in 
combination, can enable the detection and monitoring of disease progression or regression in  
NASH. The “Liver Investigation: Testing Marker Utility in Steatohepatitis” (LITMUS) 
project has been funded and brings together clinicians and scientists from academic centers 
across Europe and the European Federation of Pharmaceutical Industries and Associations 
(EFPIA) to deal with this challenge. The common goal of this group is to develop validate 
 and qualify biomarkers for NAFLD, NASH and related fibrosis. In this context, LITMUS 
will specifically seek biomarkers that (i) separate cases with non-NASH NAFLD from 
NASH; (ii) track disease progression and/or monitor response to treatment; and (iii) predict 
those at greatest risk of future progression to NASH, advanced liver fibrosis or liver-related 
morbidity. It is expected that the LITMUS project can make important contribution the field 
of NAFLD.  
Prevalence in Asia   
The NAFLD prevalence in Asia ranges from 15% to 40%, while NASH ranges from 2% to  
3% (37,38). In this context, prevalence of NAFLD in India increased from 28% in 2015 to 31% 
in 2016 and is estimated to be 30.7% in the rural region of Haryana (39). The reported 
prevalence of fatty liver has also increased in many regions of China (40) increased from 
3.87% in 1995 to 14.04% in 2002, 17.3% in 2005, and 43.65% in 2015 among Shanghai adults 
(4145). Additionally, about 5.0% of 7229 school children from the Yangtze River delta region 
in  
China had NAFLD (7.5% in boys, 2.5% in girls, 5.6% in subjects with peripheral obesity,  
12.9% in those with abdominal obesity and 44.8% in those with mixed obesity) (47).  
Furthermore, prevalence of NAFLD from Korea and Taiwan ranges from 24% to 40% and 15% 
to 27%, respectively (9). In contrast, lower prevalence rates of 9% to 18% have been reported 
from Japan (9).  
Similar to the other regions of the world, accurate data on the prevalence of NASH from Asia 
is lacking. Nevertheless, it is estimated that NASH affects 1.9% to 2.2% of general 
population in Shanghai, China (46).   
It is interesting that lean NAFLD seems to be more common in Asian countries than in  
 Western countries (Figure 3). There are differences in the profiles of Western vs Asian 
NAFLD (48), and a gradient of lean to obese NAFLD is observed in Asian countries. It 
appears that the rural areas in Asian countries have a lower prevalence of NAFLD while the 
profile is more consistent with lean NAFLD, whereas in urban areas of Asia NAFLD 
prevalence and risk profiles are similar to Western countries. (49) Although patients with 
lean NAFLD from Asia seem to have lower rates of NASH, liver fibrosis, or metabolic 
abnormalities, after adjustment for severity of visceral obesity, the clinical events and rates of 
advanced fibrosis are similar between lean and obese patients with NAFLD (49). 
Interestingly, PNPLA3rs738409 GG genotype is more common in Asian NAFLD patients 
without metabolic syndrome [50]. Since Asians are more likely to harbor the GG genotype 
than Caucasians, this may explain why the two populations have similar prevalence of 
NAFLD even though Asians lower metabolic burden. Finally, similar to the West, the 
extrahepatic manifestations of NAFLD in Asia include complications of the cardiovascular, 
gastrointestinal, and renal systems (37).  
Because Asia is a vast continent with much heterogeneity in genetic background, lifestyle and 
economic status, it is important to study and compare the epidemiology and natural history of 
NAFLD across different Asian countries. To this end, The Gut and Obesity Asia (GO ASIA) 
Workgroup has been established to serve as a platform for NAFLD researchers in Asia to 
collaborate, expand the knowledge and understanding of NAFLD and NASH by collecting 
real-world data from representative countries [51].   
Prevalence in the Middle East and Turkey:  
The prevalence of adult NAFLD in Middle Eastern countries has not been systematically 
investigated. A recent meta-analysis suggested that the prevalence of NAFLD in the Middle 
East is 31.79% (9). Additionally, data from Iran suggest that 33.9% of population have 
NAFLD (52).   
 In addition to these meta-analyses, a cross-sectional population-based study from Israel 
(N=352) suggest a prevalence of 30% for NAFLD detected by ultrasound and several 
components of the metabolic syndrome were the main risk factors (53). Another 
crosssectional study from the central part of Iran (n=483) reported 39.3% prevalence of 
NAFLD (54). These rates are significantly higher than the 15.3% reported from the rural Fars 
province of Iran (55).  
In addition to data from Israel and Iran, there is also growing evidence about the increase of 
NAFLD prevalence in Turkey. Until recently, the prevalence of NAFLD in Turkey has been 
reported from single-center, small-sized studies (56-58), reporting prevalence rates of 19.8% 
(56), 23.2% (57), and 10.6% (58). These low rates may be explained by the fact that these 
studies were conducted either in rural parts of the country (56) or in young individuals 
(57,58). In a recent unpublished epidemiological survey conducted in 113,239 apparently 
healthy subjects, the overall prevalence of NAFLD in Turkey was 48.3%. The prevalence 
was higher in those older than 50 (65.6%), males (64.0%), and in those with BMI>25 kg/m2 
(63.5%). There are also geographical differences with the Central and Eastern Anatolia 
regions showing the highest prevalence of NAFLD (57.1% and 55.7%). Importantly, the 
prevalence of NAFLD in the region has increased by 22% from 43.5% (2007) to 53.1% 
(2016) (YY 2018.) These findings indicate a rapidly increasing prevalence of NAFLD related 
to the epidemic of obesity and T2DM in these regions. It is noteworthy that in a 
hospitalbased study, the prevalence of lean NAFLD in Turkey was 7.6% (59) while an 
autopsy-based study of 330 children and adolescents suggested a prevalence of 6% with 
higher rates in overweight than in normal-weight subjects (10.6% versus 4.9%) (59, 60)  
Despite these emerging data from Israel, Turkey and Iran, there is a significant paucity of 
data from the rest of the Middle East. Nonetheless, it is important to note that the rates of 
 obesity and T2DM in the region are rapidly increasing which could certainly fuel the burden 
of NAFLD. Similar to the other reports from Asia, it is highly likely that the differences in 
the prevalence rates for this region can be explained by differences between urban and rural 
areas, as well as by the increasing burden of obesity over the years. Therefore, it can be 
hypothesized that a westernized diet and a sedentary lifestyle have led to an increase in the 
prevalence of obesity and NAFLD in the region.   
The Middle East is expected to face major challenges with NAFLD, but there is no 
systematic approach to deal with these challenges. Future large, multicenter, collaborative 
epidemiological studies are needed to more thoroughly investigate the burden of NAFLD in 
this region. A multi-prong approach leveraging social media to educate and spread awareness 
about the burden of obesity, DM and its complications such as NAFLD are necessary to help 
the region implement strategies to deal with the serious disease burden.   
Prevalence in Africa   
The burden of NAFLD in Africa appears to vary widely, although finding accurate data is 
difficult. In contrast to North America, Europe and Asia, there are very few studies on the 
epidemiology of NAFLD from Africa. A meta-analysis estimated the prevalence of NAFLD 
in Africa to be 13.48% (9). Given the paucity of data and the need to collect additional 
information about NAFLD, a member of the Global Forum sent surveys to 37 medical 
providers in 21 African and Middle Eastern countries. Based on the survey results, the 
prevalence of NAFLD appears to range from 5% (in Ethiopia) to 30% (in Saudi Arabia).  
Currently, there is no established program to provide a systematic approach to study NAFLD 
in Africa. Nevertheless, the issue of NAFLD in Africa may be important not only for its own 
risk of progressive liver disease but also because NAFLD could potentially worsen the course 
 of viral hepatitis which is quite prevalent in Africa. Future research programs to be better 
understand NAFLD in different regions of Africa are needed.  
Prevalence in Australia and Pacific Countries:   
Consistent with data from other industrialized societies, a commissioned report noted that 
NAFLD is the commonest liver disease in Australia, affecting a third of the population (5.5 
million people; 40% of adults ≥ 50 years of age and 15% of school children) (61), and 13% of 
the population of New Zealand (62). This is not surprising since Australia has one of the 
highest burdens of overweight and obesity (63.4% of adults in 2014-15) (63).   
A recent nationwide population-based survey of 9,447 individuals reported NAFLD is the 
commonest cause of abnormal liver tests. Further, 47% of the population had elevated ALT 
attributable to truncal obesity (64). Over the last decades, there has been an increasing 
appreciation of NAFLD in Australia and New Zealand by primary care physicians, with 
diagnosis and referral prompted by obesity, features of the metabolic syndrome, the detection 
of elevated liver enzymes, or a bright liver on ultrasound.  
For much of the remainder of Oceania and the Pacific, including Micronesia, Melanesia and 
Polynesia (roughly 22 nations and 10 million people), data on NAFLD/NASH prevalence are 
lacking. However, if T2DM and obesity prevalence data are any indication, this region will be 
a hotbed of NAFLD. For example, a global burden of disease study indicated that obesity 
prevalence in men exceeded 50% in Tonga and in women from Kiribati, the Federated States 
of Micronesia, Tonga, and Samoa (67). More worrisome, Pacific Island nations have the 
highest global prevalence of diabetes, including 7 of the top 10 countries and all of the top six 
[Tokelau (37.5%), Federated States of Micronesia, Marshall Islands, Kiribati, Cook Islands 
 and Vanuatu) where, in 2013, diabetes prevalence ranged from 37.5% in Tokelau to 24% in 
Vanuatu (68).  
While there are no coordinated plans to deal specifically with the challenge of NAFLD in 
Australia and New Zealand, the parallel rises in obesity and T2DM prevalence is viewed as a 
national health priority. Frequent campaigns have been undertaken by Federal and State 
agencies promoting healthy food intake and physical activity, while obesity and T2DM 
research is targeted for research funding. Such efforts have borne some fruit as Australian 
national nutrition surveys between 1995 and 2011 reported for 12,000 participants’ positive 
changes, including the consumption of more fruit, vegetables, peas, beans, nuts, seeds, pulses, 
brown and wholegrain cereals, as well as reduced intake of sugars (65). Consistently, shorter- 
and longer-term declines in the availability and intake of added sugars and sugar-sweetened 
beverages has been reported (66). Major efforts are now underway to reduced sedentary 
behavior by encouraging physical activity. At an investigator-led level, consortiums are being 
formed (often as part of international collaborations) to study NAFLD natural history, 
pathophysiology, and to establish biobanks for biomarker development.  
Global Incidence of NAFLD  
here are few accurate data on NAFLD incidence in the general population. Some rates have 
been estimated to range from 28.01 per 1000 person-years to 52.34 per 1000 person- (9). For 
more details, please see supplementary material.   
Clinical Outcomes  
Complications of NAFLD/NASH have been reported worldwide. The rate of cirrhosis is 
lower in Asia compared to Western countries. In Hong Kong, 3.7% of NAFLD patients had 
 fibrosis or cirrhosis. In biopsy-proven NAFLD from mainland China 1.97%-2.97% reported 
cirrhosis. (71-72) In India, 2% of NAFLD patients had cirrhosis, while in Japan, 2.1% had 
significant fibrosis (73).   
In contrast, an estimated 10-15% of NAFLD patients from US and Europe have advanced 
fibrosis (9). A study using NHANES (1999–2002 and 2009–2012 cycles) reported a 2.5-fold 
increase in the prevalence of NASH-associated cirrhosis and 2-fold increase in the prevalence 
of NAFLD-associated advanced fibrosis. The authors then predicted a 6% increase in 
NAFLD and >100% increase in advanced liver diseases over the next 15 years. (74)  Liver-
related mortality   
Patients with NAFLD have an increased risk of liver-specific death—primarily those with 
histologically proven NASH. In a study of 289 NAFLD patients who were followed for 150 
months, those with NASH had >6-fold higher risk of liver-related death than NAFLD without 
NASH (75). Liver related mortality was increased 2-fold if T2DM and or histologic NASH 
was present. (75) Other studies have independently associated insulin resistance and MS with 
all-cause, liver-specific, and cardiovascular mortality (6-9). Although NASH is associated 
with increased liver-related mortality, it is the stage of fibrosis that increases the risk of death 
in NAFLD patients. (12, 76-79)   
lthough cardiovascular disease is the leading cause of death in NAFLD, a recent multicenter 
study suggests that this is true for non-cirrhotic cases [80]. Among 458 patients with 
biopsyproven NAFLD from Europe, Asia, Australia and America, 37 died during a mean 
follow-up of 5.5 years. Liver complications accounted for 50% of the deaths in patients with 
F3 fibrosis, 73% in those with early cirrhosis, and 100% in those with advanced cirrhosis. 
This suggests that in NAFLD patients with advanced fibrosis, liver mortality will dominate.  
 Cardiovascular disease  
The cause of death for most patients with NAFLD is related to cardiovascular diseases. (81)  
When patients with NAFLD and liver fibrosis (stages 3 or 4) were followed for an average of 
26 years, they had a 1.55-fold increase in risk for cardiovascular disease compared to 
individuals without NAFLD (81-85). Similarly, 117 NAFLD patients and 507 controls from  
South China were followed for 4 years showing higher rates of cardiovascular mortality in  
NAFLD, especially if MS was present (0.19% and 0.17%, P=0.005). (86)   
There has been intense research to understand the underlying mechanisms connecting 
NAFLD to cardiovascular diseases (87). Prospective, long-term studies are needed to 
determine whether the presence of NAFLD, NASH, or advanced NASH (stage 3 and 4) is 
independently associated with cardiovascular mortality and if treatment of these liver 
diseases can modify the cardiovascular outcomes.  
HCC   
AFLD is the third-most common cause of cancer-related death worldwide and seventh-most 
common cause in the US (88). In a study of the Surveillance, Epidemiology, and End Results 
database, investigators found that among the 4949 patients with HCC, 701 patients had 
NAFLD, providing a prevalence of NAFLD-associated HCC of 14.1% (19).The cumulative 
incidence of HCC among patients with NAFLD and cirrhosis has been reported to range from 
2.4% to 12.8% over a median follow-up period of 3.2 to 7.2 years (89, 90). For more details 
regarding HCC, please see supplementary material.  
Liver Transplantation   
NASH is the most rapidly growing indication for LT in the US (20,94-99). Despite the 
resurgence of ALD, NASH is the second-leading indication for LT. For more detail about LT 
and NASH, please see supplementary material.  
 Special Topics in Epidemiology of NAFLD  
NAFLD in Diabetics  
A recent systematic review of studies, comprising 88,978 persons with diabetes from 28 
countries, found the overall global prevalence of NAFLD among persons with diabetes to be 
57.80%. The highest rate was in Europe (66.19%) and the lowest was in Africa (13.20%) 
(100). In this study, the overall prevalence of NASH among diabetic patients from whom 
biopsies were available was 65.26%. In addition, the prevalence of advanced fibrosis (≥ F3) 
was 15.05% (100). In addition, prevalence of NAFLD diabetics can range from 42.6% in UK 
patients (30) to 60-70% in Italy (31). In the absence of biopsy, the prevalence of NAFLD and 
advanced fibrosis in diabetics (N=1918), as determined by vibration controlled transient 
elastography, is estimated to be 72.8% and 17.7% [102]. Furthermore, a community-based 
study from Netherlands estimated that significant fibrosis by elastography was present in 
8.4% of NAFLD subjects which was associated with T2DM (32). These and other studies 
have confirmed the high prevalence of NAFLD, NASH and advanced in patients with T2DM 
(100-101).  
Interactions between NAFLD and metabolic syndrome  
In addition to T2DM, patients with NAFLD have a high prevalence of metabolic syndrome 
(MS) and patients with MS have a high prevalence of NAFLD. This phenomenon has led 
some to consider NAFLD as the hepatic manifestation of MS. Findings from many studies 
worldwide corroborate this strong and reciprocal association.   
A study conducted in Asia reported that the incidence of fatty liver increased by 14% in 
patients with at least 3 components of MS compared to patients with fewer than 3 features 
(37). Prevalence of MS among lean NAFLD was 36.1% in Shanghai, China, and fatty liver 
appears to be a better predictor than overall obesity and abdominal obesity for the clustering 
 of risk factors for MS (43). In east China, 358 NAFLD patients and 788 matched controls 
were followed for 6 years. Incidence of obesity (47.6% vs 19.5%), hypertension (69.6% vs 
16.3%), hypertriglyceridemia (39.1% vs 16.3%), hypercholesterolemia (24.5% vs 17.3%), 
T2DM (20.3% vs 5.2%) and MS (56.3% vs 16.3%) were significantly higher in NAFLD 
group than controls. (42)  
These data were confirmed in a systematic review which reported a prevalence of 34% for 
MS in patients with NAFLD (9). In fact, similar rates are reported worldwide. Of patients 
with NAFLD in Asia, Europe, the Middle East, North America, and South America, 34%, 
62%, 31%, 33%, and 37% have been reported to have MS (9).  
n addition to high reciprocal prevalence rates, patients with NAFLD with multiple features of 
MS are also at higher risk for advanced fibrosis and death than patients with NAFLD without 
MS (100-106). A multivariate analysis of biopsies from 432 patients with NAFLD 
independently associated increases in aspartate and alanine aminotransferases, presence of 
diabetes, male sex, and Caucasian ethnicity with the presence of moderate to severe 
histologic fibrosis (P<.0001). Additionally, an increase in the number of MS components 
(T2DM, hypertension, and visceral obesity) increased the likelihood of advanced fibrosis in a 
stepwise fashion- finding confirmed using NHANES III data. (101,106).  
In addition to higher risk for advanced fibrosis in patients with NAFLD, the presence of MS 
increases the risk for liver-related mortality and all-cause mortality (7). Other analysis of 
NHANES III data determined MS independently increased liver-related mortality and overall 
mortality (7, 75). These data indicate that not only the presence of metabolic derangement but 
also its severity have negative effects on long-term outcomes of patients with NAFLD.  
 NAFLD in non-obese or lean individuals  
Although NAFLD is closely linked to obesity and MS, approximately 5%–8% of patients 
with NAFLD in Western countries are considered lean (8,107). These NAFLD patients still 
have abnormal glucose tolerance, and about one-third have a diagnosis of diabetes (64). 
Interestingly, a higher proportion of lean individuals with NAFLD have the PNPLA3 
rs738409 GG genotype and low serum concentrations of adiponectin, compared to controls 
(107). These data indicate that lean patients with NAFLD have dysregulated glucose 
metabolism and adipose tissue, as well as the PNPLA3 rs738409 GG genotype (107).   
The similarities of lean NAFLD to obese or overweight NAFLD indicate a spectrum of 
metabolic abnormalities in such a way that obese patients with NAFLD might have more 
severe abnormalities whereas lean NAFLD patients have less severe metabolic defects. A 
recent systematic review concluded that lean and obese patients with NAFLD have a 
common altered metabolic profile but lean persons with NAFLD have excess abdominal 
adipose tissue (108).  
Lean NAFLD in Asia appears to differ from that of the West. Approximately 20% of the  
Asian population has lean NAFLD (37). In China, patients with lean NAFLD had a lower 
BMI and waist circumstance than obese NAFLD, but these were higher than individuals 
without NAFLD (109). Furthermore, patients with lean NAFLD also had a significantly 
higher visceral adiposity index and greater odds for having T2DM, hypertension, MS, and 
central obesity than individuals without NAFLD (66). Similar findings have reported from  
Korea, India, Iran, and Turkey. (110-112)  
Despite the spectrum of metabolic abnormalities in patients with lean or obese NAFLD, it is 
likely that other genetic and environmental factors affect risk. Studies are needed to 
investigate the role of gut microbiota and environmental factors, including exposures to 
antibiotics, in development and progression of NAFLD.  
 Pediatric NAFLD  
Based on analyses of surrogate makers, the prevalence of NAFLD in children has been 
estimated to range from 2.6% to 17.3%. (113) In an autopsy series study of children, 
investigators determined the overall prevalence of NAFLD to be 9.6%, but rates increased 
with age. NAFLD was more common in boys, but the highest rate was in Hispanic children  
(11.8%), while the lowest rate was in African-American children (1.5%). (114)   
A longitudinal study of NHANES data estimated that the prevalence of NAFLD in 
adolescents increased from 3.9% in 1988–1994 to 10.7% in 2007–2010 (P<.0001), affecting 
all race/ethnic groups and both sexes. (115) Again, the prevalence of NAFLD increased with 
age, BMI, Mexican-American ethnicity, and male sex. However, among obese adolescences, 
the odds of NAFLD were higher with increased age, BMI, Mexican-American ethnicity, and 
male sex. In 2007–2010, 48.1% of all obese male adolescents and 56.0% of obese Mexican- 
American male adolescents were suspected to have NAFLD. (116)  
Children seem to have a different presentation of advanced NAFLD than adults. In a 
crosssectional study of 813 children from the Nonalcoholic Steatohepatitis Clinical Research  
Network with biopsy-proven NAFLD, researchers found that children with zone 1 steatosis  
(18%) had significantly more advanced fibrosis and were younger than children without zone  
1 steatosis. In children with steatosis in zone 3 (32%), a higher proportion had steatohepatitis 
(30%) than children with steatosis in zone 1 (6%) (P<.001) (114). It is also important to note 
that presence and progression of NASH in pediatric patients accelerates with T2DM (117- 
Since there are few data from long-term studies (> 2 years) or studies with liver biopsy data, 
the current pediatric data may not represent real-world pediatric patients. Additionally, 
 noninvasive fibrosis scoring systems designed for adults do not adequately predict which 
children will develop liver fibrosis. Thus, pediatric markers are needed to determine risk of 
fibrosis in children.  
Patient Reported Outcomes in NAFLD  
In addition to clinical outcomes, PROs are important to consider for NAFLD patients (120). 
NAFLD has been found to cause a significant decrease in quality of life as measured by 
various tools (16,120-122). In addition, some PRO impairment may be associated with 
NAFLD comorbidities such as depression or the stage of fibrosis (123-125).  
Although NASH itself can reduce HRQL scores, treatment of NASH can also affect HRQL. 
Preliminary data from selonsertib in NASH suggested that reductions in hepatic fibrosis and 
the amount of collagen were associated with improvements in HRQL (124). Although 
generic HRQL instruments have been used to study NAFLD and NASH, a disease-specific  
HRQL instrument (CLDQ NAFLD-NASH) was recently developed and validated (122, 126). 
CLDQ-NAFLD-NASH was developed using an established rigorous methodology (patients’ 
interviews, focus groups, item reduction, factor analysis, and psychometric testing). As such, 
the CLDQ-NAFLD-NASH is now being used in clinical trials of NASH to capture patients’ 
perspectives about their disease and treatment.  (126).   
Economic effects of NAFLD and NASH  
NAFLD is also associated with a significant economic burden. For details regarding the 
Economic burden of NAFLD, please see the supplementary material.  
Conclusions  
The prevalence of NAFLD as well as the genetic and environmental factors that determine its 
associated risk varies worldwide. The progressive form of NAFLD or NASH is associated 
 with liver-related mortality, reduced HRQL, and substantial economic burdens. In the context 
of growing burden of NASH worldwide, there is a lack effective treatment regimen and 
validated non-invasive diagnostic, prognostic and dynamic biomarkers. For details about 
authors’ statement about future of NAFLD/NASH, please see supplementary material. 
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